Spots Global Cancer Trial Database for A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors
Official Title: A Phase I First Time in Human Open Label Study of GSK3745417 Administered With and Without Anticancer Agents in Participants With Advanced Solid Tumors
Study ID: NCT03843359
Conditions
Study Description
Brief Summary: This study aims to evaluate the safety, tolerability, and preliminary clinical activity and establish a recommended dose of GSK3745417 administered alone (Part 1A) or co-administered (Part 2A) with dostarlimab in participants with refractory/relapsed solid tumors. Both parts will consist of a dose escalation phase.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
GSK Investigational Site, Houston, Texas, United States
GSK Investigational Site, Melbourne, Victoria, Australia
GSK Investigational Site, Toronto, Ontario, Canada
GSK Investigational Site, Bordeaux Cedex, , France
GSK Investigational Site, Villejuif cedex, , France
GSK Investigational Site, Tokyo, , Japan
GSK Investigational Site, Tokyo, , Japan
GSK Investigational Site, Seoul, , Korea, Republic of
GSK Investigational Site, Amsterdam, , Netherlands
GSK Investigational Site, Amsterdam, , Netherlands
GSK Investigational Site, Barcelona, , Spain
GSK Investigational Site, Madrid, , Spain
GSK Investigational Site, Madrid, , Spain
Contact Details
Name: GSK Clinical Trials
Affiliation: GlaxoSmithKline
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
